ExCellThera Inc.

The European Medicines Agency has begun fast-track reviews of the EU marketing applications for sipavibart, AstraZeneca ’s drug for preventing COVID-19 in immunocompromised patients, and dorocubicel,

Gamida Cell Ltd. ’s Omisirge (omidubicel-onlv) will be the first substantially modified cord blood-based stem cell graft source for allogeneic hematopoietic progenitor cell transplantation following F

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GC Pharma, Speragen To Co-Develop SSADH

A total of 20 investigational drugs secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme in 2020, with some of them targeting new therapeutic areas and indications. The